Innovent - Eli Lilly's Sintilimab Combo Shows Sustained Survival Benefit In Lung...

[cafead]

via

• Innovent Biologics Inc OTCIVBIY and Eli Lilly And Co LLY 0.55% have announced new and updated data from the ORIENT-11 Phase 3 study of sintilimab as first-line treatment of nonsquamous non-small cell lung cancer (NSCLC).
• The trial assessed sintilimab in combination with pemetrexed and platinum chemotherapy.

article source